

Mexico Hemostats Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2789.00
- Five User License \$3909.00
- Corporate License \$5099.00

Report description:

The Mexico hemostats market was valued at USD 160.27 Million in 2024 driven by the rapid technological advancements, with innovations in hemostatic agents such as fibrin sealants and advanced topical hemostats across the region. It is expected to grow at a CAGR of 5.50% during the forecast period of 2025-2034 and attain a market value of USD 273.76 Million by 2034.

The market is growing steadily, shaped by advances in surgical technology and the country's shifting health profile. Hospitals are adopting newer hemostatic products, particularly fibrin sealants and advanced topical agents, which offer faster application and better outcomes in complex surgeries. This shift is driven by both public and private healthcare providers looking to improve surgical efficiency and patient recovery. Chronic diseases are a major factor. Cardiovascular disease, diabetes, and obesity are all on the rise in Mexico, contributing to a higher volume of surgical interventions, from bypass surgeries and angioplasties to amputations and wound care. These procedures often involve significant blood loss, making effective hemostasis critical.

Mexico Hemostats Market Overview

Hemostats are widely used in Mexico to control bleeding during surgeries, trauma cases, and wound management, ensuring patient safety and reducing complications. They are essential in procedures like orthopedic, gynecological, cardiovascular, and general surgeries, especially given Mexico's rising rates of chronic diseases, cesarean deliveries, and trauma incidents, which drive the need for effective hemostatic solutions in hospitals and surgical centers. The Mexico hemostats market is expected to grow at a CAGR of 5.50% during the forecast period of 2025-2034.

Mexico Hemostats Market Growth Drivers

Adoption of Innovative Hemostats to Boost Market Value

Rising gastrointestinal disorder prevalence and increasing demand for minimally invasive procedures are key drivers for the market. For instance, in February 2021, EndoClot Plus, Inc. announced FDA approval for its EndoClot Polysaccharide Hemostatic

Scotts International. EU Vat number: PL 6772247784

System (PHS), a starch-based powder that quickly forms a gelled matrix to control GI bleeding via endoscopy. As this product gains global adoption, including in emerging markets like Mexico, it is likely to bolster advanced hemostatic solution adoption, driving significant market growth in the forecast period.

Mexico Hemostats Market Trends

The market is expanding due to rising cancer cases and increasing trauma-related surgical needs.

Rising Cancer Burden Fueling Mexico Hemostats Market Growth

In 2022, Mexico recorded over 207,000 new cancer cases and nearly 96,210 deaths, highlighting the country's growing oncology burden. With prevalent cases exceeding 577,000, surgical intervention remains critical, especially for prostate and breast cancer. This rising demand for surgeries directly fuels the need for effective intraoperative bleeding control, thereby driving the adoption of hemostats in Mexico's healthcare landscape and contributing significantly to market growth during the forecast period.

Increased Spinal Trauma Cases Bolstering Mexico Hemostats Market Demand

A 2022 study conducted at a Level III trauma center in Mexico reported 55 cases of spinal gunshot injuries over a two-year period (2018-2020), with a mortality rate of 5.45%. These findings underscore the significant burden of spinal injuries in Mexico, highlighting the need for effective hemostatic agents to manage bleeding and improve patient outcomes. The increasing incidence of trauma cases is expected to drive the demand for advanced hemostatic solutions, contributing to the growth of the hemostats market in Mexico during the forecast period.

Mexico Hemostats Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

- Thrombin Based Hemostats
- Oxidized Regenerated Cellulose Based Hemostats
- Combination Hemostats
- Gelatin Based
- Collagen Based
- Others

Market Breakup by Formulation

- Matrix and Gel Hemostats
- Sponge Hemostats
- Powder Hemostats
- Sheet and Pad
- Others

Market Breakup by Application

- Cardiovascular and Cardiothoracic

Scotts International, EU Vat number: PL 6772247784

- Gynecological
- Urology
- Orthopedic Surgery
- General Surgery
- Plastic Surgery
- Ear, Nose and Throat (ENT), Head and Neck Surgery
- Others

Market Breakup by Indication

- Closure
- Surgery

Market Breakup by End User

- Hospitals and Clinics
- Ambulatory Surgical Centers
- Casualty Care Centers
- Others

Mexico Hemostats Market Share

Matrix and Gel Based Hemostats to Lead the Market Share by Formulation

Matrix and gel hemostats are likely to hold the largest share of the market. Their dominance is attributed to their superior efficacy in controlling bleeding during complex surgeries, versatility across various surgical specialties, and rapid adoption by surgeons seeking advanced solutions. As per the analysis by Expert Market Research, the global hemostats market size is expected to grow at a CAGR of 6.40% during the forecast period of 2025-2034. Additionally, matrix and gel formulations are preferred for their ease of use and ability to conform to irregular wound surfaces, supporting better surgical outcomes.

Leading Players in the Mexico Hemostats Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Johnson and Johnson Services Inc.

Headquartered in New Brunswick, New Jersey, Johnson and Johnson Services Inc. was established in 1886. The company is a global healthcare leader, offering a diverse range of medical devices, pharmaceuticals, and consumer health products. In Mexico's hemostats market, its Ethicon division delivers advanced hemostatic solutions like SURGICEL, widely used in surgeries for effective bleeding control.

Baxter International

Baxter International, founded in 1931 and headquartered in Deerfield, Illinois, is a leading global MedTech company. In the Mexico hemostats market, Baxter provides a robust portfolio of hemostatic agents and sealants, including innovative products like Floseal and the recently launched Hemopatch Sealing Hemostat, which offers rapid, effective hemostasis for both open and minimally

Page 3/9

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

invasive surgeries.

Pfizer Inc.

Pfizer Inc., established in 1849 and based in New York City, is a renowned pharmaceutical and biotechnology company. In Mexico, Pfizer contributes to the hemostats market through its specialized biopharmaceuticals and partnerships, offering advanced solutions that support surgical teams in managing bleeding and improving patient outcomes during complex procedures.

B. Braun SE

B. Braun SE, founded in 1839 and headquartered in Melsungen, Germany, is a global leader in healthcare products and services. In Mexico's hemostats market, B. Braun offers a comprehensive range of surgical hemostatic agents and wound care solutions, supporting hospitals and surgical centers with reliable, innovative products for effective intraoperative bleeding management.

Other key players in the market include Becton, Dickinson and Company (BD), Medtronic plc, and Stryker Corporation, among others.

Key Questions Answered in the Mexico Hemostats Market

- What was the Mexico hemostats market value in 2024?
- What is the Mexico hemostats market forecast outlook for 2025-2034?
- What are the major factors aiding the Mexico hemostats market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Mexico hemostats market trends?
- Which type will lead the market segment?
- Which formulation will lead the market segment?
- Which application will lead the market segment?
- Which indication will lead the market segment?
- Which end user will lead the market segment?
- Who are the key players involved in the Mexico hemostats market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

What was the Mexico hemostats market value in 2024?

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Hemostats Market Overview
- 3.1 Latin America Hemostats Market Overview

Scotts International, EU Vat number: PL 6772247784

- 3.1.1 Latin America Hemostats Market Historical Value (2018-2024)
- 3.1.2 Latin America Hemostats Market Forecast Value (2025-2034)
- 3.2 Mexico Hemostats Market Overview
- 3.2.1 Mexico Hemostats Market Historical Value (2018-2024)
- 3.2.2 Mexico Hemostats Market Forecast Value (2025-2034)
- 4 Mexico Hemostats Market Landscape*
- 4.1 Mexico Hemostats Market: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Mexico Hemostats Market: Product Landscape
- 4.2.1 Analysis By Type
- 4.2.2 Analysis By Formulation
- 4.2.3 Analysis By Application
- 5 Mexico Hemostats Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 PESTEL Analysis
- 5.3.1 Political
- 5.3.2 Economic
- 5.3.3 Social
- 5.3.4 Technological
- 5.3.5 Legal
- 5.3.6 Environment
- 5.4 Porter's Five Forces Model
- 5.4.1 Bargaining Power of Suppliers
- 5.4.2 Bargaining Power of Buyers
- 5.4.3 Threat of New Entrants
- 5.4.4 Threat of Substitutes
- 5.4.5 Degree of Rivalry
- 5.5 Key Demand Indicators
- 5.6 Key Price Indicators
- 5.7 Industry Events, Initiatives, and Trends
- 5.8 Value Chain Analysis
- 6 Mexico Hemostats Market Segmentation (218-2034)
- 6.1 Mexico Hemostats Market (2018-2034) by Type
- 6.1.1 Market Overview
- 6.1.2 Thrombin Based Hemostats
- 6.1.3 Oxidized Regenerated Cellulose Based Hemostats
- 6.1.4 Combination Hemostats
- 6.1.5 Gelatin Based
- 6.1.6 Collagen Based
- 6.1.7 Others

Scotts International, EU Vat number: PL 6772247784

- 6.2 Mexico Hemostats Market (2018-2034) by Formulation
- 6.2.1 Market Overview
- 6.2.2 Matrix & Gel Hemostats
- 6.2.3 Sponge Hemostats
- 6.2.4 Powder Hemostats
- 6.2.5 Sheet and Pad
- 6.2.6 Others
- 6.3 Mexico Hemostats Market (2018-2034) by Application
- 6.3.1 Market Overview
- 6.3.2 Cardiovascular and Cardiothoracic
- 6.3.3 Gynecological
- 6.3.4 Urology
- 6.3.5 Orthopedic Surgery
- 6.3.6 General Surgery
- 6.3.7 Plastic Surgery
- 6.3.8 Ear, nose and throat (ENT), Head and Neck Surgery
- 6.3.9 Others
- 6.4 Mexico Hemostats Market (2018-2034) by Indication
- 6.4.1 Market Overview
- 6.4.2 Closure
- 6.4.3 Surgery
- 6.5 Mexico Hemostats Market (2018-2034) by End User
- 6.5.1 Market Overview
- 6.5.2 Hospitals & Clinics
- 6.5.3 Ambulatory Surgical Centers
- 6.5.4 Casualty Care Centers
- 6.5.5 Others
- 7 Regulatory Framework
- 8 Patent Analysis
- 8.1 Analysis By Drug Type of Patent
- 8.2 Analysis by Publication Year
- 8.3 Analysis by Issuing Authority
- 8.4 Analysis by Patent Age
- 8.5 Analysis by CPC Analysis
- 8.6 Analysis by Patent Valuation
- 8.7 Analysis by Key Players
- 9 Funding and Investment Analysis
- 9.1 Analysis by Funding Instances
- 9.2 Analysis by Drug Class of Funding
- 9.3 Analysis by Funding Amount
- 9.4 Analysis by Leading Players
- 9.5 Analysis by Leading Investors
- 9.6 Analysis by Geography
- 10 Strategic Initiatives
- 10.1 Analysis by Partnership Instances
- 10.2 Analysis by Drug Class of Partnership
- 10.3 Analysis by Leading Players

Scotts International, EU Vat number: PL 6772247784

- 10.4 Analysis by Geography
- 11 Supplier Landscape
- 11.1 Johnson and Johnson Services Inc.
- 11.1.1 Financial Analysis
- 11.1.2 Product Portfolio
- 11.1.3 Demographic Reach and Achievements
- 11.1.4 Company News and Development
- 11.1.5 Certifications
- 11.2 Baxter Interntaional
- 11.2.1 Financial Analysis
- 11.2.2 Product Portfolio
- 11.2.3 Demographic Reach and Achievements
- 11.2.4 Company News and Development
- 11.2.5 Certifications
- 11.3 Pfizer Inc.
- 11.3.1 Financial Analysis
- 11.3.2 Product Portfolio
- 11.3.3 Demographic Reach and Achievements
- 11.3.4 Company News and Development
- 11.3.5 Certifications
- 11.4 B. Braun SE
- 11.4.1 Financial Analysis
- 11.4.2 Product Portfolio
- 11.4.3 Demographic Reach and Achievements
- 11.4.4 Company News and Development
- 11.4.5 Certifications
- 11.5 Becton, Dickinson and Company (BD)
- 11.5.1 Financial Analysis
- 11.5.2 Product Portfolio
- 11.5.3 Demographic Reach and Achievements
- 11.5.4 Company News and Development
- 11.5.5 Certifications
- 11.6 Medtronic plc
- 11.6.1 Financial Analysis
- 11.6.2 Product Portfolio
- 11.6.3 Demographic Reach and Achievements
- 11.6.4 Company News and Development
- 11.6.5 Certifications
- 11.7 Stryker Corporation
- 11.7.1 Financial Analysis
- 11.7.2 Product Portfolio
- 11.7.3 Demographic Reach and Achievements
- 11.7.4 Company News and Development
- 11.7.5 Certifications
- 12 Mexico Hemostats Market Distribution Model (Additional Insight)
- 12.1 Overview
- 12.2 Potential Distributors

Scotts International. EU Vat number: PL 6772247784

Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com				
	Page 8/9			

12.3 Key Parameters for Distribution Partner Assessment 13 Key Opinion Leaders (KOL) Insights (Additional Insight)



Print this form

To place an Order with Scotts International:

Mexico Hemostats Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 250 pages | EMR Inc.

- Send as a scann	levant blank fields and ed email to support@sc	=	.com			
-						
ORDER FORM:						
Select license	License					Price
	Single User License					\$2789.00
	Five User License	Five User License				\$3909.00
	Corporate License	Corporate License				\$5099.00
					VAT	
					Total	
** VAT will be added at	: 23% for Polish based com	npanies, individuals a	and EU based con	npanies who are	e unable to provide a	valid EU Vat N
_	: 23% for Polish based com			npanies who are	e unable to provide a	valid EU Vat N
Email*	: 23% for Polish based com	Pho	one*	npanies who are	e unable to provide a	valid EU Vat N
Email* [: 23% for Polish based com	Pho		npanies who are	e unable to provide a	valid EU Vat N
Email* First Name* Ob title*	: 23% for Polish based com	Pho Las	one* t Name*		e unable to provide a	valid EU Vat N
Email* First Name* ob title* Company Name*	: 23% for Polish based com	Pho	one* t Name* Vat / Tax ID / N		e unable to provide a	valid EU Vat N
Email* [: 23% for Polish based com	Pho Las	one* t Name* Vat / Tax ID / N		e unable to provide a	valid EU Vat N
Email* First Name* ob title* Company Name*	: 23% for Polish based com	Pho Las EU City	one* t Name* Vat / Tax ID / N		e unable to provide a	valid EU Vat N
Email* First Name* Ob title* Company Name* Address*	: 23% for Polish based com	Pho Las EU City	one* t Name* Vat / Tax ID / N /* untry*			valid EU Vat N
Email* First Name* Ob title* Company Name* Address*	: 23% for Polish based com	Pho Las EU City Cou	one* t Name* Vat / Tax ID / N /* untry*	P number*		valid EU Vat N
Email* First Name* ob title* Company Name* Address*	: 23% for Polish based com	Pho Las EU City Cou	one* t Name* Vat / Tax ID / N /* untry* :e	P number*		valid EU Vat N

Scotts International. EU Vat number: PL 6772247784